Founders Fund

Nucleus operates a biotechnology research platform focused on next-generation consumer genetic testing and analysis. The company allows users to upload their genetic information obtained from established providers and employs proprietary algorithms to calculate polygenic risk scores and assess disease risk based on genetic variants. Utilizing whole-genome sequencing, Nucleus delivers comprehensive genetic analysis, facilitating advancements in human health and medicine. The results are presented on a user-friendly platform, making complex genetic information accessible and understandable for users.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Siren Biotechnology is a biotechnology company focused on cancer treatment through an integrated therapeutic modality that combines adeno-associated virus–based gene therapy with cytokine immunotherapy. The approach delivers targeted cytokines to tumors, aiming to activate both innate and adaptive immune responses while addressing toxicity and off-target effects. By uniting gene delivery with immunotherapy in a single modality, the company seeks to enhance tumor cell elimination and improve long-term anti-tumor immunity, potentially reducing recurrence in cancer patients.

NewLimit focuses on developing epigenetic reprogramming medicines to treat age-related diseases and extend the human health span. It uses single-cell genomics, machine learning, and functional assays to identify epigenetic targets and develop messenger RNA-based therapies for improving metabolic function in liver cells.

Nucleus operates a biotechnology research platform focused on next-generation consumer genetic testing and analysis. The company allows users to upload their genetic information obtained from established providers and employs proprietary algorithms to calculate polygenic risk scores and assess disease risk based on genetic variants. Utilizing whole-genome sequencing, Nucleus delivers comprehensive genetic analysis, facilitating advancements in human health and medicine. The results are presented on a user-friendly platform, making complex genetic information accessible and understandable for users.

MyOme develops a genetic testing technology that provides comprehensive health insights through whole genome sequencing. Its platform offers detailed reports on disease risk and medication response, accompanied by independent physician reviews and genetic counseling. The company ensures ongoing updates using advanced technologies, empowering individuals to make informed health decisions while maintaining data privacy and security.

Ultima Genomics is a biotechnology company established in 2016 and headquartered in Newark, California. It specializes in genome-scale sequencing technology, focusing on providing analytical services to various enterprises. By employing an open substrate, Ultima Genomics creates a vast, low-cost reaction surface that facilitates billions of reads without relying on expensive flow cells or complex fluidic systems. The company utilizes specialized sequencing hardware combined with machine learning techniques to ensure reproducible and accurate results. This innovative approach enables clients to obtain genomic reports at scale, enhancing the speed and efficiency of sequencing while significantly reducing costs. Ultima Genomics aims to harness the potential of genomic information to drive advancements in biology and improve human health.

Synthego is a biotechnology company specializing in genome engineering. It offers integrated hardware, software, bioinformatics, chemistries, and molecular biology platforms to advance basic research and therapeutic development. Its products include engineered cells, CRISPR kits, and bioinformatics tools for gene knockout, target validation, and disease modeling. Synthego serves scientists globally, with sales through distributors in multiple countries and online.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Synthego is a biotechnology company specializing in genome engineering. It offers integrated hardware, software, bioinformatics, chemistries, and molecular biology platforms to advance basic research and therapeutic development. Its products include engineered cells, CRISPR kits, and bioinformatics tools for gene knockout, target validation, and disease modeling. Synthego serves scientists globally, with sales through distributors in multiple countries and online.

Indee Labs develops hardware and platform technologies for gene delivery to immune cells, with the aim of enabling the rapid development and scalable manufacture of gene-modified cell therapies, including CAR-T cells. The company focuses on non-viral delivery methods to introduce small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells, supporting biopharmaceutical research and manufacturing while maintaining high cell viability and function. Its technology has progressed with collaboration from national facilities and through participation in biotech incubators and accelerators. Indee Labs maintains an international footprint, with an office in Sydney and lab space in Berkeley, reflecting its cross-regional development and manufacturing focus.

Counsyl is a health technology company specializing in DNA screening services for individuals and families. The company focuses on providing critical information that can significantly influence health outcomes, enabling proactive measures and informed decision-making. With a strong commitment to accessibility, Counsyl has screened over 500,000 patients and collaborated with more than 6,000 healthcare professionals through its accredited clinical laboratory. It employs sophisticated technology and custom robotic automation to analyze blood and saliva samples with precision and efficiency. The platform not only aids in family planning through its Family Prep Screen but also encompasses informed pregnancy and cancer screening. Recognized for its innovative approach, Counsyl has received accolades such as the Wall Street Journal’s Innovation Award for Medicine and has been listed among Scientific American's "Top 10 World Changing Ideas." The company combines the expertise of scientists, engineers, and clinical professionals to enhance communication between patients and healthcare providers regarding medical results.

Synthego is a biotechnology company specializing in genome engineering. It offers integrated hardware, software, bioinformatics, chemistries, and molecular biology platforms to advance basic research and therapeutic development. Its products include engineered cells, CRISPR kits, and bioinformatics tools for gene knockout, target validation, and disease modeling. Synthego serves scientists globally, with sales through distributors in multiple countries and online.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Genesis Healthcare Co. is a privately-owned genetic testing and research company founded in 2004 and headquartered in Tokyo, Japan, with additional offices in Singapore and Taiwan. The company is recognized as a market leader in consumer genetics in Japan, offering its services under the brand "GeneLife." Genesis Healthcare possesses the largest genetic database in Japan and Asia, encompassing over 988,000 individuals and more than 1,500 diseases. The company utilizes advanced technologies such as PCR, Microarray, and NGS for research and clinically validated genetic testing services. In addition to its commercial offerings, Genesis Healthcare collaborates with government agencies to establish genetic testing guidelines, ensuring accuracy and the protection of individuals' genetic information. By promoting preventive healthcare through genetic testing, Genesis Healthcare aims to enhance public health outcomes across Southeast Asia.

Epinomics Inc. specializes in advancing personalized medicine by leveraging big data analytics and proprietary epigenomics technology. Founded in 2013 and located in Menlo Park, California, the company focuses on decoding the human genome to enhance drug development and clinical applications. By utilizing innovative DNA sequencing technology, Epinomics aims to improve existing methodologies in the field, facilitating deeper scientific research and the development of clinical applications. As of March 31, 2018, Epinomics operates as a subsidiary of 10X Genomics, Inc., furthering its mission to revolutionize healthcare through precision medicine.

Synthego is a biotechnology company specializing in genome engineering. It offers integrated hardware, software, bioinformatics, chemistries, and molecular biology platforms to advance basic research and therapeutic development. Its products include engineered cells, CRISPR kits, and bioinformatics tools for gene knockout, target validation, and disease modeling. Synthego serves scientists globally, with sales through distributors in multiple countries and online.

Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.

Counsyl is a health technology company specializing in DNA screening services for individuals and families. The company focuses on providing critical information that can significantly influence health outcomes, enabling proactive measures and informed decision-making. With a strong commitment to accessibility, Counsyl has screened over 500,000 patients and collaborated with more than 6,000 healthcare professionals through its accredited clinical laboratory. It employs sophisticated technology and custom robotic automation to analyze blood and saliva samples with precision and efficiency. The platform not only aids in family planning through its Family Prep Screen but also encompasses informed pregnancy and cancer screening. Recognized for its innovative approach, Counsyl has received accolades such as the Wall Street Journal’s Innovation Award for Medicine and has been listed among Scientific American's "Top 10 World Changing Ideas." The company combines the expertise of scientists, engineers, and clinical professionals to enhance communication between patients and healthcare providers regarding medical results.

Pathway Genomics Corporation is a clinical laboratory based in San Diego, California, that specializes in providing genetic testing services to healthcare professionals and their patients both domestically and internationally. The company offers a variety of tests, including liquid biopsy, hereditary cancer assessments, and pharmacogenomics, which evaluates how individuals respond to specific medications. Additionally, Pathway Genomics provides services related to general health and wellness, carrier screening, and corporate wellness initiatives. Their testing portfolio addresses numerous health concerns, including cancer risk, cardiac health, inherited diseases, and responses to nutrition and exercise. Pathway Genomics is recognized for its commitment to quality, holding CAP accreditation and establishing strategic partnerships with organizations like Standard Process and Rainbow Genomics. The company was incorporated in 2008, reflecting its ongoing role in advancing personalized medicine.

NewLimit focuses on developing epigenetic reprogramming medicines to treat age-related diseases and extend the human health span. It uses single-cell genomics, machine learning, and functional assays to identify epigenetic targets and develop messenger RNA-based therapies for improving metabolic function in liver cells.